ライフサイエンスコーパス: iron chelate

1 r iron acquisition from low-molecular-weight iron chelates.

2 ke from transferrin and low molecular weight iron chelates.

3 The iron chelating abilities of these molecules have been ch

4 ependent, likely due to differences in their iron-chelating abilities.

5 eptides smaller than 5kDa were evaluated for iron chelating ability through measurements of iron solu

6 ants lacking the sch gene cluster lost their iron-chelating ability as quantified by the chrome azuro

7 The R100 sample demonstrated the highest iron-chelating ability during biotransformation until 12

8 , possessing a druglike chemotype and modest iron-chelating ability.

9 to act via cryptic off-target antioxidant or iron chelating activities.

10 All the fractions demonstrated low iron chelating activity and did not inhibit oxidation in

11 eeds were analyzed for antioxidant activity, Iron chelating activity and total phenolic content.

12 In contrast, reducing power and iron chelating activity seemed to be caused by peptides.

13 activity (78% and 82%, respectively), while iron chelating activity was the highest in fractions A1

14 ical scavenging activity, reducing power and iron chelating activity.

15 ging assay showed 71.3% inhibition and 65.8% Iron chelating activity.

16 an seeds are good source of antioxidants and Iron chelating activity.

17 scavenging activity and possessed increased iron-chelating activity and reducing power.

18 elating defect; demonstrating production and iron-chelating activity for both siderophores.

19 Iron-chelating activity was higher in purified peptide f

20 contents were positively correlated with the iron-chelating activity.

21 eptides were purified and analysed for their iron-chelating activity.

22 rk contrast to this behavior, addition of an iron chelating agent (citrate) to the protein solution r

23 ideal clinical setting, patient population, iron chelating agent, and dosing regimen.

24 effect was augmented by desferroioxamine, an iron chelating agent.

25 evaluation both as a potential orally active iron-chelating agent and as a parenteral iron chelator.

26 Deferoxamine (DFO), an iron-chelating agent clinically used to treat iron toxic

27 rable with deferoxamine, a clinically useful iron-chelating agent.

28 red when choosing the appropriate dose of an iron-chelating agent.

29 The actual role of iron chelating agents may be to promote a long enough su

30 ADO appeared less sensitive to iron chelating agents or transition metal exposure than

31 Well-known as specific iron chelating agents produced by bacteria, it is shown

32 ric oxide and free-radical formation, use of iron chelating agents, the potential role of hypoxia-ind

33 is via the secretion of low-molecular-weight iron-chelating agents (siderophores).

34 These results demonstrate that iron-chelating agents such as PCIH may be of benefit in

35 AcnD activity was lost after incubation with iron-chelating agents, and no AcnD activity was observed

36 l treatments with conventional growth medium iron chelate and SPIONs (as iron source), indicated no s

37 rpose To synthesize two low-molecular-weight iron chelates and compare their T1 contrast effects with

38 nding is likely due to the 21-aminosteroid's iron-chelating and cell-permeating abilities, and sugges

39 ate showed the strongest radical scavenging, iron-chelating and reducing activity.

40 tes on the function of FbpA as a carrier for iron chelates as well as "naked" or free iron as origina

41 levels by supplementation with a variety of iron chelates at >1 muM, including iron(III) dicitrate,

42 Hydroxyl radicals generated by the iron chelate attached at position 187 resulted in DNA st

43 and appearance of the high-spin signal from iron chelated by 6-OHDA oxidation products; (2) spectrop

44 vitamin B(12) (cyano-cobalamin [CN-Cbl]) and iron chelates by use of sequential active transport proc

45 The use of site-specifically tethered iron chelates can reveal protein-protein interactions, b

46 rption spectroscopy (AAS) was used to verify iron chelating capability of nanogels.

47 ation of iron (Fe)-transferrin generates new iron chelates capable of catalyzing hydroxyl radical (.O

48 in total polyphenol and flavonoid contents, iron chelating capacity, and antioxidant properties of t

49 f calcium and magnesium causes a decrease in iron chelating capacity; however, 61% chelating capacity

50 mpeting ions and increasing viscosity on the iron-chelating capacity and antioxidant efficacy of this

51 Materials retained iron-chelating capacity even in solutions of 2700 cP, si

52 es eliciting activities rely on their strong iron-chelating capacity.

53 The iron-chelating catechol siderophore vibriobactin of the

54 ticles, "umbrella" conjugates, siderophores (iron-chelating compounds), and monoclonal antibodies wer

55 ne-di(o-hydroxyphenyl-acetic acid), or other iron-chelating compounds.

56 tants KP1344 (tonB) and RA1051 (exbBD) under iron-chelated conditions further support the roles of th

57 uced growth under static (limited aeration), iron-chelated conditions, while a yfe feo double mutant

58 mutant Escherichia coli strain, 1017, under iron-chelated conditions.

59 A. actinomycetemcomitans cells to grow under iron-chelated conditions.

60 harboring afeABCD promoted cell growth under iron-chelated conditions.

61 significance, our understanding of how these iron-chelating cyclic hexapeptides are assembled by non-

62 tion of both systems resulted in an in vitro iron-chelating defect; demonstrating production and iron

63 former were added with a phytocomplex having iron chelating, DPPH, and FRAP activity, obtained from o

64 These properties of the novel multimodal iron-chelating drugs possessing neuroprotective/neuritog

65 d multifunctional, nontoxic, brain-permeable iron-chelating drugs, M30 and HLA20, possessing the N-pr

66 d liver iron, and from the availability of 3 iron-chelating drugs.

67 ify uptake mechanisms for Fe(3+), Fe(2+) and iron chelates (e.g. siderophore and haem iron complexes)

68 iomass production, and FeHBED (water-soluble iron chelate) exhibited unique effects on energy metabol

69 Using tethered iron chelate (Fe-BABE) derivatives of the enhancer-depen

70 The iron chelate FeBABE [iron (S)-1-(p-bromoacetamidobenzyl)

71 aspergillic acid, deoxyaspergillic acid, and iron-chelating ferriaspergillin.

72 i siderophore receptor, FepA, that binds the iron chelate ferric enterobactin and colicins B and D.

73 insoluble ferric hydroxide and the mammalian iron chelates ferritin and transferrin.

74 occal TdTs facilitate utilization of iron or iron chelates from host-derived proteins, including tran

75 dramatically reduced by mimosine due to its iron-chelating function.

76 ds iron in a hexadentate fashion using a new iron-chelating gamma-amino acid.

77 t moderately higher concentrations, however, iron chelates generated similar contrast effects at T1-w

78 To test this hypothesis, we designed an iron-chelating glycocluster incorporating a tetrahydroxa

79 ed according to the chemical nature of their iron-chelating group (ie, catechol, hydroxamate, alpha-h

80 ygenases are involved in the biosynthesis of iron-chelating hydroxamate-containing siderophores that

81 h is subsequently formylated to generate the iron-chelating hydroxamates of the siderophore pyoverdin

82 Transport of iron chelates is accomplished by TonB-dependent transpor

83 ability to acquire siderophores and/or haem iron chelates is beneficial.

84 Specifically, we focused on the role of iron chelating ligands in promoting chemical oxidation o

85 the dynamic microbial production and loss of iron-chelating ligands.

86 ir inactivation results in growth defects in iron-chelated media, without affecting acinetobactin bio

87 derivative 1644, which was unable to grow in iron-chelated media.

88 ons in this gene abrogate growth of SAB11 on iron-chelated media.

89 bic conditions, and in iron-supplemented and iron-chelated medium.

90 s been believed to protect the heart via its iron-chelating metabolite ADR-925.

91 ty, has traditionally been attributed to its iron-chelating metabolite.

92 yclodextrin (beta-CD) and ferrocene (Fc) and iron chelating moieties composed of deferoxamine (DFO) i

93 This work expands the repertoire of iron-chelating moieties in microbial siderophores.

94 ctive moiety of rasagiline (Azilect) and the iron-chelating moiety of VK28.

95 Small iron-chelating molecules called siderophores were select

96 Siderophores are iron-chelating molecules that solubilize Fe(3+) for micr

97 paired (100- to 2500-fold) adsorption of the iron chelate more strongly.

98 The nicotianamine-iron chelate [NA-Fe(2+)], which is found in many plant-b

99 e method is based on the reaction of NO with iron chelates of N-methylglucamine dithio-carbamate (MGD

100 The iron-chelating peptide vibriobactin of the pathogenic Vi

101 These results show that iron-chelating peptides are generated after chickpea pro

102 Iron-chelating peptides were isolated using immobilized

103 cavenging activity, higher on green tea, and iron chelating potential, higher on L. algarvense.

104 Tethered iron chelate probes attached to amino and carboxyl-termi

105 racterization of M606 not only confirmed its iron-chelating properties but also revealed its ability

106 d this effect is fully related to its potent iron-chelating property in the organelle.

107 resulting in simultaneously secretion of the iron chelating protein lipocalin 2 (LCN2) and protons, w

108 Here, we show that the iron-chelating pyoverdines, siderophores produced by env

109 The iron chelate reagent Fe-BABE was conjugated onto unique

110 an genital infection using the intracellular iron-chelating reagent deferoxamine mesylate (Desferal).

111 1 structure in a complex with the biliverdin-iron chelate show two major differences.

112 Pathogenic mycobacteria synthesize iron chelating siderophores named mycobactin and carboxy

113 endent transporters (TBDTs), which transport iron-chelating siderophores and vitamin B(12) across the

114 he environment by secreting strain-specific, iron-chelating siderophores termed pyoverdines (PVD).

115 y accepted mode of iron acquisition, and Mtb iron-chelating siderophores, mycobactin, have been known

116 ococcus aureus, produce low-molecular-weight iron-chelating siderophores.

117 oteins form energized, gated pores that bind iron chelates (siderophores) and internalize them.

118 incorporates the common 2,3-dihydroxybenzoyl iron-chelating subunit, PB is novel in that it incorpora

119 clinical trials evaluating the usefulness of iron-chelating therapy in critical illness and sepsis.

120 icipated, of whom 216 (84.7%) were receiving iron-chelating therapy.

121 re receptors are components of high-affinity iron-chelate transport systems in gram-negative bacteria

122 atients with long-standing disease requiring iron-chelating treatment and a history of splenectomy ne

123 FTH1 overexpression as well as iron-chelating treatment by Deferoxamine were able to re

124 Iron efflux via an iron-chelating tricarboxylic acid cycle intermediate pro

125 rrier protein domains during assembly of the iron-chelating virulence factor, yersiniabactin of the p